ClinicalTrials.gg
CompletedNCT01096667Updated Sep 13, 2018Results posted

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

A Phase 2 interventional study of Placebo to Ertuglilflozin 1 or 5 mg and Ertugliflozin 1 mg in Diabetes Mellitus, Type 2 and Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
12th of 28
194 · median 83
Started
2010
with 4 others
Phase 2
3 of 28
none open now
Registered
4th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 5 that started in 2010, is one of 3 in phase 2, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and hypertension. Participants in the study will receive 1 of 5 treatments for 28 days (either placebo, 1 of 3 doses of ertugliflozin [1, 5, or 25 mg], or the approved drug hydrochlorothiazide [HCTZ]). The primary hypothesis of the study was that ertugliflozin was superior to placebo on the change from baseline in average, 24-hour systolic blood pressure (SBP) on Day 28.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Hypertension

Keywords

  • type 2 diabetes
  • hypertension
  • ambulatory blood pressure monitoring
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 2 diabetes and hypertension
  • Medically stable
  • On at least 1 (and up to 2) oral diabetes drugs
  • And up to 2 medicines for blood pressure control

Exclusion criteria

Exclusion Criteria:

  • Participants with type 1 diabetes
  • Heart attack
  • Stroke
  • Uncontrolled blood pressure
  • Significant kidney disease
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
194 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.

    Drug: Placebo to Ertuglilflozin 1 or 5 mg · Drug: Placebo to HCTZ · Drug: Placebo to ertuglilflozin 25 mg

  • Experimental
    Ertugliflozin 1 mg

    Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days

    Drug: Ertugliflozin 1 mg · Drug: Placebo to HCTZ · Drug: Placebo to ertuglilflozin 25 mg

  • Experimental
    Ertugliflozin 5 mg

    Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days

    Drug: Ertugliflozin 5 mg · Drug: Placebo to HCTZ · Drug: Placebo to ertuglilflozin 25 mg

  • Experimental
    Ertugliflozin 25 mg

    Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days

    Drug: Placebo to Ertuglilflozin 1 or 5 mg · Drug: Ertugliflozin 25 mg · Drug: Placebo to HCTZ

  • Active comparator
    HCTZ 12.5mg

    HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days

    Drug: Placebo to Ertuglilflozin 1 or 5 mg · Drug: HCTZ 12.5mg · Drug: Placebo to ertuglilflozin 25 mg

Interventions

  • DrugPlacebo to Ertuglilflozin 1 or 5 mg

    Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days

  • Ertugliflozin tablet 1 mg once daily for 28 days

  • Ertugliflozin tablet 5 mg once daily for 28 days

  • Ertugliflozin tablet 25 mg once daily for 28 days

  • Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days

  • DrugPlacebo to HCTZ

    Placebo to HCTZ 12.5 mg capsule once daily for 28 days

  • DrugPlacebo to ertuglilflozin 25 mg

    Placebo to ertuglilflozin tablet 25 mg once daily for 28 days

06

What researchers measure

Primary outcomes

  1. Baseline 24-hour Average Systolic Blood Pressure (SBP)

    Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM).

    Time frame: 24 hours

  2. Change From Baseline on 24-hour Average SBP at Week 4

    Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF).

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Baseline Average Daytime and Nighttime SBP

    Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

    Time frame: Daytime: 16 hours; Nighttime: 8 hours

  2. Change From Baseline on Daytime Average SBP at Week 4

    Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.

    Time frame: Baseline and Week 4

  3. Change From Baseline on Nighttime Average SBP at Week 4

    Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

    Time frame: Baseline and Week 4

  4. Baseline Seated, Triplicate Trough SBP

    Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures.

    Time frame: Baseline

  5. Change From Baseline in Seated, Triplicate Trough SBP at Week 4

    Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.

    Time frame: Baseline and Week 4

  6. Baseline 24-hour, Daytime and Nightime Average Diastolic Blood Pressure (DBP)

    Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

    Time frame: up to 24 hours

  7. Change From Baseline on 24-hour Average DBP at Week 4

    Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF.

    Time frame: Baseline and Week 4

  8. Change From Baseline on Daytime Average DBP at Week 4

    Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.

    Time frame: Baseline and Week 4

  9. Change From Baseline on Nighttime Average DBP at Week 4

    Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

    Time frame: Baseline and Week 4

  10. Baseline Seated, Triplicate Trough DBP

    Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures.

    Time frame: Baseline

  11. Change From Baseline in Seated, Triplicate Trough DBP at Week 4

    Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.

    Time frame: Baseline and Week 4

  12. Baseline 24-hour, Daytime and Nightime Average Heart Rate

    Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

    Time frame: up to 24 hours

  13. Change From Baseline on 24-hour Average Heart Rate at Week 4

    Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM.

    Time frame: Baseline and Week 4

  14. Change From Baseline on Daytime Average Heart Rate at Week 4

    Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.

    Time frame: Baseline and Week 4

  15. Change From Baseline on Nighttime Average Heart Rate at Week 4

    Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

    Time frame: Baseline and Week 4

  16. Baseline Seated, Triplicate Trough Heart Rate

    Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures.

    Time frame: Baseline

  17. Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 4

    Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.

    Time frame: Baseline and Week 4

  18. Baseline 24-hour Average Urinary Glucose Excretion

    Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as \>20 hours and \<28 hours).

    Time frame: 24 hours

  19. Change From Baseline on 24-hour Urinary Glucose Excretion at Week 4

    Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as \>20 hours and \<28 hours). In the case of missing data, LOCF.

    Time frame: Baseline and Week 4

  20. Baseline Fasting Plasma Glucose (FPG)

    For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).

    Time frame: Baseline

  21. Change From Baseline in FPG at Week 4

    For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).

    Time frame: Baseline and Week 4

  22. Change From Baseline in FPG at Week 2

    For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).

    Time frame: Baseline and Week 2

  23. Number of Participants Who Experienced an Adverse Event (AE)

    An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug.

    Time frame: Up to 63 days (including run-in, treatment period, and follow-up)

  24. Number of Participants Who Discontinued Study Drug Due to an AE

    An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE.

    Time frame: Up to 28 days (treatment period)

07

Results

Posted Dec 13, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Started3939383939
Treated3839383939
Completed3637363639
Not completed32230
Withdrew: Lost to follow-up11100
Withdrew: Withdrawal by subject10010
Withdrew: Reason not available01110
Withdrew: Protocol violation00010
Withdrew: Not treated10000

Outcome measures

PrimaryBaseline 24-hour Average Systolic Blood Pressure (SBP)

Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM).

Time frame:
24 hours
Reported as:
Mean · mmHg
Baseline 24-hour Average Systolic Blood Pressure (SBP)
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Baseline 24-hour Average Systolic Blood Pressure (SBP)136.11 ± 15.298133.13 ± 10.868135.08 ± 12.073135.59 ± 11.929139.55 ± 11.941
PrimaryChange From Baseline on 24-hour Average SBP at Week 4

Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF).

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline on 24-hour Average SBP at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on 24-hour Average SBP at Week 40.26 (-1.31 to 1.70)-2.71 (-4.15 to -1.33)-3.73 (-5.30 to -2.18)-3.42 (-4.86 to -1.99)-2.95 (-4.39 to -1.51)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.034 (P-value is one-sided.) · Difference in least squares means: -2.97 · 80% CI -5.05 to -0.89Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.010 (P-value is one-sided.) · Difference in least squares means: -4.00 · 80% CI -6.17 to -1.82Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.012 (P-value is one-sided.) · Difference in least squares means: -3.69 · 80% CI -5.78 to -1.60Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.024 (P-value is one-sided.) · Difference in least squares means: -3.21 · 80% CI -5.30 to -1.13Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
SecondaryBaseline Average Daytime and Nighttime SBP

Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

Time frame:
Daytime: 16 hours; Nighttime: 8 hours
Reported as:
Mean · mmHg
Baseline Average Daytime and Nighttime SBP
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Daytime139.95 ± 15.107136.85 ± 11.361138.89 ± 11.724139.56 ± 12.343143.32 ± 12.637
Nighttime127.54 ± 16.858125.15 ± 12.180126.37 ± 13.956127.13 ± 13.553131.68 ± 12.912
SecondaryChange From Baseline on Daytime Average SBP at Week 4

Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline on Daytime Average SBP at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on Daytime Average SBP at Week 40.82 (-0.90 to 2.34)-2.88 (-4.49 to -1.44)-3.61 (-5.30 to -1.94)-4.17 (-5.72 to -2.63)-3.10 (-4.66 to -1.57)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.018 (P-value is one-sided.) · Difference in least squares means: -3.70 · 80% CI -5.94 to -1.46Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.008 (P-value is one-sided.) · Difference in least squares means: -4.43 · 80% CI -6.78 to -2.09Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.002 (P-value is one-sided.) · Difference in least squares means: -4.99 · 80% CI -7.24 to -2.74Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.013 (P-value is one-sided.) · Difference in least squares means: -3.92 · 80% CI -6.16 to -1.67Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
SecondaryChange From Baseline on Nighttime Average SBP at Week 4

Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline on Nighttime Average SBP at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on Nighttime Average SBP at Week 4-0.29 (-2.28 to 1.71)-2.48 (-4.33 to -0.60)-3.47 (-5.53 to -1.39)-2.31 (-4.21 to -0.40)-2.30 (-4.20 to -0.40)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.152 (P-value is one-sided.) · Difference in least squares means: -2.19 · 80% CI -4.93 to 0.54Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.078 (P-value is one-sided.) · Difference in least squares means: -3.18 · 80% CI -6.06 to -0.30Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.174 (P-value is one-sided.) · Difference in least squares means: -2.02 · 80% CI -4.79 to 0.74Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.174 (P-value is one-sided.) · Difference in least squares means: -2.01 · 80% CI -4.77 to 0.74Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
SecondaryBaseline Seated, Triplicate Trough SBP

Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures.

Time frame:
Baseline
Reported as:
Mean · mmHg
Baseline Seated, Triplicate Trough SBP
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Baseline Seated, Triplicate Trough SBP135.17 ± 14.183134.23 ± 13.631137.31 ± 14.834135.25 ± 13.452138.07 ± 12.958
SecondaryChange From Baseline in Seated, Triplicate Trough SBP at Week 4

Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated, Triplicate Trough SBP at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline in Seated, Triplicate Trough SBP at Week 41.24 (-0.93 to 3.41)-2.77 (-4.95 to -0.60)-5.92 (-8.12 to -3.73)-4.96 (-7.15 to -2.77)-3.13 (-5.26 to -1.00)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · Mixed Model for Repeated Measures · p = 0.047 (P-value is one-sided.) · Difference in least squares means: -4.01 · 80% CI -7.09 to -0.94With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs Ertugliflozin 5 mg · Mixed Model for Repeated Measures · p = 0.002 (P-value is one-sided.) · Difference in least squares means: -7.16 · 80% CI -10.25 to -4.07With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs Ertugliflozin 25 mg · Mixed Model for Repeated Measures · p = 0.005 (P-value is one-sided.) · Difference in least squares means: -6.20 · 80% CI -9.28 to -3.11With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs HCTZ 12.5mg · Mixed Model for Repeated Measures · p = 0.033 (P-value is one-sided.) · Difference in least squares means: -4.37 · 80% CI -7.41 to -1.33With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
SecondaryBaseline 24-hour, Daytime and Nightime Average Diastolic Blood Pressure (DBP)

Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

Time frame:
up to 24 hours
Reported as:
Mean · mmHg
Baseline 24-hour, Daytime and Nightime Average Diastolic Blood Pressure (DBP)
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
24-hr81.89 ± 9.65578.67 ± 8.60080.18 ± 8.65580.36 ± 8.65082.66 ± 9.459
Daytime85.32 ± 10.12781.77 ± 8.92583.47 ± 9.16483.59 ± 9.29585.87 ± 9.884
Nighttime74.24 ± 9.71772.05 ± 9.33073.05 ± 9.03473.28 ± 8.76075.76 ± 10.042
SecondaryChange From Baseline on 24-hour Average DBP at Week 4

Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline on 24-hour Average DBP at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on 24-hour Average DBP at Week 40.77 (-0.25 to 1.75)-1.89 (-2.81 to -0.95)-2.34 (-3.37 to -1.31)-1.50 (-2.45 to -0.55)-1.42 (-2.37 to -0.48)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.007 (P-value is one-sided.) · Difference in least squares means: -2.66 · 80% CI -4.03 to -1.29Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.003 (P-value is one-sided.) · Difference in least squares means: -3.11 · 80% CI -4.55 to -1.67Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.018 (P-value is one-sided.) · Difference in least squares means: -2.27 · 80% CI -3.65 to -0.88Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.021 (P-value is one-sided.) · Difference in least squares means: -2.19 · 80% CI -3.56 to -0.82Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.
SecondaryChange From Baseline on Daytime Average DBP at Week 4

Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline on Daytime Average DBP at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on Daytime Average DBP at Week 40.87 (-0.24 to 1.85)-2.12 (-3.13 to -1.18)-1.88 (-2.96 to -0.80)-1.77 (-2.77 to -0.78)-1.69 (-2.67 to -0.70)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.004 (P-value is one-sided.) · Difference in least squares means: -2.99 · 80% CI -4.43 to -1.55Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.010 (P-value is one-sided.) · Difference in least squares means: -2.75 · 80% CI -4.26 to -1.24Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.010 (P-value is one-sided.) · Difference in least squares means: -2.64 · 80% CI -4.09 to -1.19Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.011 (P-value is one-sided.) · Difference in least squares means: -2.57 · 80% CI -4.00 to -1.13Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.
SecondaryChange From Baseline on Nighttime Average DBP at Week 4

Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline on Nighttime Average DBP at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on Nighttime Average DBP at Week 41.02 (-0.39 to 2.44)-1.48 (-2.78 to -0.15)-2.52 (-3.98 to -1.06)-0.84 (-2.19 to 0.51)-0.55 (-1.95 to 0.71)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.048 (P-value is one-sided.) · Difference in least squares means: -2.50 · 80% CI -4.43 to -0.57Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.013 (P-value is one-sided.) · Difference in least squares means: -3.54 · 80% CI -5.58 to -1.51Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.111 (P-value is one-sided.) · Difference in least squares means: -1.88 · 80% CI -3.82 to 0.09Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.148 (P-value is one-sided.) · Difference in least squares means: -1.58 · 80% CI -3.51 to 0.36Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
SecondaryBaseline Seated, Triplicate Trough DBP

Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures.

Time frame:
Baseline
Reported as:
Mean · mmHg
Baseline Seated, Triplicate Trough DBP
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Baseline Seated, Triplicate Trough DBP84.89 ± 9.46283.08 ± 7.55783.79 ± 7.90483.89 ± 8.29084.72 ± 8.043
SecondaryChange From Baseline in Seated, Triplicate Trough DBP at Week 4

Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated, Triplicate Trough DBP at Week 4
mmHgPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline in Seated, Triplicate Trough DBP at Week 40.30 (-0.97 to 1.58)-0.90 (-2.18 to 0.37)-0.75 (-2.03 to 0.54)-2.71 (-4.00 to -1.43)-2.54 (-3.79 to -1.29)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · Mixed Measures Repeated Model · p = 0.196 (P-value is one-sided.) · Difference in least squares means: -1.20 · 80% CI -3.01 to 0.60With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs Ertugliflozin 5 mg · Mixed Measures Repeated Model · p = 0.229 (P-value is one-sided.) · Difference in least squares means: -1.05 · 80% CI -2.86 to 0.77With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs Ertugliflozin 25 mg · Mixed Measures Repeated Model · p = 0.017 (P-value is one-sided.) · Difference in least squares means: -3.02 · 80% CI -4.83 to -1.20With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs HCTZ 12.5mg · Mixed Measures Repeated Model · p = 0.021 (P-value is one-sided.) · Difference in least squares means: -2.84 · 80% CI -4.63 to -1.06With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
SecondaryBaseline 24-hour, Daytime and Nightime Average Heart Rate

Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

Time frame:
up to 24 hours
Reported as:
Mean · beats per minute
Baseline 24-hour, Daytime and Nightime Average Heart Rate
beats per minutePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
24-hr81.11 ± 9.48680.74 ± 6.95079.68 ± 10.08179.41 ± 9.06379.08 ± 9.216
Daytime84.43 ± 9.74383.74 ± 7.04482.71 ± 10.40582.18 ± 9.13681.95 ± 9.470
Nighttime74.05 ± 9.87174.44 ± 8.13373.16 ± 10.20573.49 ± 10.03473.03 ± 9.736
SecondaryChange From Baseline on 24-hour Average Heart Rate at Week 4

Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Beats per minute
Change From Baseline on 24-hour Average Heart Rate at Week 4
Beats per minutePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on 24-hour Average Heart Rate at Week 41.00 (-0.21 to 2.16)-1.22 (-2.45 to -0.25)1.07 (-0.16 to 2.29)-1.39 (-2.52 to -0.26)-0.56 (-1.68 to 0.56)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.039 (P-value is one-sided.) · Difference in least squares means: -2.22 · 80% CI -3.83 to -0.61Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.521 (P-value is one-sided.) · Difference in least squares means: 0.07 · 80% CI -1.63 to 1.77Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.031 (P-value is one-sided.) · Difference in least squares means: -2.39 · 80% CI -4.02 to -0.75Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.110 (P-value is one-sided.) · Difference in least squares means: -1.56 · 80% CI -3.19 to 0.07Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
SecondaryChange From Baseline on Daytime Average Heart Rate at Week 4

Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Beats per minute
Change From Baseline on Daytime Average Heart Rate at Week 4
Beats per minutePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on Daytime Average Heart Rate at Week 41.58 (0.25 to 2.83)-1.80 (-3.09 to -0.70)1.10 (-0.24 to 2.43)-1.07 (-2.31 to 0.15)-0.06 (-1.22 to 1.22)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.007 (P-value is one-sided.) · Difference in least squares means: -3.38 · 80% CI -5.13 to -1.63Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.370 (P-value is one-sided.) · Difference in least squares means: -0.48 · 80% CI -2.33 to 1.38Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.029 (P-value is one-sided.) · Difference in least squares means: -2.65 · 80% CI -4.43 to -0.87Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.118 (P-value is one-sided.) · Difference in least squares means: -1.64 · 80% CI -3.42 to 0.13Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
SecondaryChange From Baseline on Nighttime Average Heart Rate at Week 4

Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Beats per minute
Change From Baseline on Nighttime Average Heart Rate at Week 4
Beats per minutePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on Nighttime Average Heart Rate at Week 4-0.18 (-1.63 to 1.25)-0.15 (-1.76 to 0.91)1.43 (-0.07 to 2.92)-1.99 (-3.38 to -0.63)-1.24 (-2.70 to 0.00)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.506 (P-value is one-sided.) · Difference in least squares means: 0.02 · 80% CI -1.96 to 2.00Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.838 (P-value is one-sided.) · Difference in least squares means: 1.61 · 80% CI -0.49 to 3.71Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.123 (P-value is one-sided.) · Difference in least squares means: -1.82 · 80% CI -3.82 to 0.19Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.246 (P-value is one-sided.) · Difference in least squares means: -1.07 · 80% CI -3.06 to 0.93Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
SecondaryBaseline Seated, Triplicate Trough Heart Rate

Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures.

Time frame:
Baseline
Reported as:
Mean · beats per minute
Baseline Seated, Triplicate Trough Heart Rate
beats per minutePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Baseline Seated, Triplicate Trough Heart Rate77.07 ± 9.71378.73 ± 8.44677.30 ± 11.74975.63 ± 9.55077.97 ± 11.462
SecondaryChange From Baseline in Seated, Triplicate Trough Heart Rate at Week 4

Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · beats per minute
Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 4
beats per minutePlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 42.34 (0.85 to 3.82)-1.86 (-3.35 to -0.38)1.22 (-0.28 to 2.71)-1.51 (-3.01 to -0.01)-0.99 (-2.44 to 0.46)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · Mixed Model for Repeated Measures · p = 0.005 (P-value is one-sided.) · Difference in least squares means: -4.20 · 80% CI -6.30 to -2.10With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs Ertugliflozin 5 mg · Mixed Model for Repeated Measures · p = 0.248 (P-value is one-sided.) · Difference in least squares means: -1.12 · 80% CI -3.23 to 0.99With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs Ertugliflozin 25 mg · Mixed Model for Repeated Measures · p = 0.010 (P-value is one-sided.) · Difference in least squares means: -3.84 · 80% CI -5.95 to -1.73With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
  • Placebo vs HCTZ 12.5mg · Mixed Model for Repeated Measures · p = 0.020 (P-value is one-sided.) · Difference in least squares means: -3.33 · 80% CI -5.40 to -1.25With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.
SecondaryBaseline 24-hour Average Urinary Glucose Excretion

Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as \>20 hours and \<28 hours).

Time frame:
24 hours
Reported as:
Mean · grams/day
Baseline 24-hour Average Urinary Glucose Excretion
grams/dayPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Baseline 24-hour Average Urinary Glucose Excretion13.35 ± 22.9139.97 ± 20.0858.04 ± 13.13517.56 ± 29.1016.96 ± 8.562
SecondaryChange From Baseline on 24-hour Urinary Glucose Excretion at Week 4

Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as \>20 hours and \<28 hours). In the case of missing data, LOCF.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · grams/day
Change From Baseline on 24-hour Urinary Glucose Excretion at Week 4
grams/dayPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline on 24-hour Urinary Glucose Excretion at Week 44.15 (-3.50 to 11.81)46.33 (38.79 to 53.88)64.54 (56.77 to 72.31)74.49 (66.87 to 82.11)-0.48 (-7.76 to 6.80)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value rounded to thousandths.) · Difference in least squares means: 42.18 · 80% CI 31.42 to 52.94Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 5 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value rounded to thousandths.) · Difference in least squares means: 60.39 · 80% CI 49.47 to 71.31Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs Ertugliflozin 25 mg · ANCOVA · p = 0.000 (P-value is one-sided. P-value rounded to thousandths.) · Difference in least squares means: 70.34 · 80% CI 59.58 to 81.10Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
  • Placebo vs HCTZ 12.5mg · ANCOVA · p = 0.713 (P-value is one-sided.) · Difference in least squares means: -4.63 · 80% CI -15.22 to 5.96Based on ANCOVA with treatment as fixed effect and baseline as a covariate.
SecondaryBaseline Fasting Plasma Glucose (FPG)

For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).

Time frame:
Baseline
Reported as:
Mean · mg/dL
Baseline Fasting Plasma Glucose (FPG)
mg/dLPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Baseline Fasting Plasma Glucose (FPG)169.47 ± 51.073158.38 ± 40.806158.29 ± 42.465172.03 ± 55.878156.87 ± 36.541
SecondaryChange From Baseline in FPG at Week 4

For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 4
mg/dLPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline in FPG at Week 44.39 (-2.16 to 10.94)-13.70 (-20.35 to -7.06)-30.41 (-37.12 to -23.71)-31.03 (-37.74 to -24.32)3.79 (-2.74 to 10.31)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · Mixed Model for Repeated Measures · p = 0.007 (P-value is one-sided.) · Difference in least squares means: -18.10 · 80% CI -27.45 to -8.75With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.
  • Placebo vs Ertugliflozin 5 mg · Mixed Model for Repeated Measures · p = 0.000 (P-value is one-sided. P-value rounded to thousandths.) · Difference in least squares means: -34.81 · 80% CI -44.19 to -25.43With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.
  • Placebo vs Ertugliflozin 25 mg · Mixed Model for Repeated Measures · p = 0.000 (P-value is one-sided. P-value rounded to thousandths.) · Difference in least squares means: -35.42 · 80% CI -44.78 to -26.07With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.
  • Placebo vs HCTZ 12.5mg · Mixed Model for Repeated Measures · p = 0.467 (P-value is one-sided.) · Difference in least squares means: -0.61 · 80% CI -9.86 to 8.65With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.
SecondaryChange From Baseline in FPG at Week 2

For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 2
mg/dLPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Change From Baseline in FPG at Week 2-5.44 (-11.93 to 1.04)-10.98 (-17.69 to -4.26)-22.45 (-29.23 to -15.67)-32.03 (-38.66 to -25.40)3.21 (-3.32 to 9.74)
Statistical analysis
  • Placebo vs Ertugliflozin 1 mg · Mixed Model for Repeated Measures · p = 0.224 (P-value is one-sided.) · Difference in least squares means: -5.54 · 80% CI -14.89 to 3.82With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.
  • Placebo vs Ertugliflozin 5 mg · Mixed Model for Repeated Measures · p = 0.011 (P-value is one-sided.) · Difference in least squares means: -17.00 · 80% CI -26.39 to -7.61With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.
  • Placebo vs Ertugliflozin 25 mg · Mixed Model for Repeated Measures · p = 0.000 (P-value is one-sided. P-value rounded to thousandths.) · Difference in least squares means: -26.59 · 80% CI -35.84 to -17.33With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.
  • Placebo vs HCTZ 12.5mg · Mixed Model for Repeated Measures · p = 0.886 (P-value is one-sided.) · Difference in least squares means: 8.65 · 80% CI -0.56 to 17.87With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug.

Time frame:
Up to 63 days (including run-in, treatment period, and follow-up)
Reported as:
Number · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Number of Participants Who Experienced an Adverse Event (AE)98151210
SecondaryNumber of Participants Who Discontinued Study Drug Due to an AE

An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE.

Time frame:
Up to 28 days (treatment period)
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mg
Number of Participants Who Discontinued Study Drug Due to an AE00010

Adverse events

Collected over Up to 63 days (including screening and run-in [pre-randomization], treatment period, and follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/38 (2.6%)3/38 (7.9%)
Ertugliflozin 1 mg—0/39 (0%)4/39 (10.3%)
Ertugliflozin 5 mg—0/38 (0%)8/38 (21.1%)
Ertugliflozin 25 mg—0/39 (0%)6/39 (15.4%)
HCTZ 12.5mg—0/39 (0%)6/39 (15.4%)
Pre-randomization—1/194 (0.5%)10/193 (5.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mgPre-randomization
Extradural haematomaInjury, poisoning and procedural complications1/380/390/380/390/390/194
Skull fractureInjury, poisoning and procedural complications1/380/390/380/390/390/194
HematuriaGeneral disorders0/380/390/380/390/391/194
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mgPre-randomization
Genital infection fungalInfections and infestations0/380/393/381/390/390/193
NasopharyngitisInfections and infestations0/380/392/380/390/390/193
Upper respiratory tract infectionInfections and infestations2/381/391/380/390/393/193
Urinary tract infectionInfections and infestations1/381/392/381/390/391/193
AthralgiaMusculoskeletal and connective tissue disorders0/380/392/380/390/392/193
DizzinessNervous system disorders2/380/390/381/390/393/193
FatigueGeneral disorders0/380/391/382/390/390/193
PyrexiaGeneral disorders0/380/390/380/392/390/193
Musculoskeletal painMusculoskeletal and connective tissue disorders0/382/390/380/392/390/193
HeadacheNervous system disorders0/380/391/380/392/394/193

Baseline characteristics

Baseline analysis population includes participants who received at least 1 dose of blinded treatment regimen.

Age, Customized
Age, Customized(Participants)PlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mgTotal
<18 years000000
Between 18 and 44 years3435116
Between 45 and 64 years3434323434168
65 years and older113049
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboErtugliflozin 1 mgErtugliflozin 5 mgErtugliflozin 25 mgHCTZ 12.5mgTotal
Female141213121162
Male2427252728131
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015 Aug;17(8):805-8. doi: 10.1111/dom.12486. Epub 2015 Jun 17. PubMed 25951755 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Feb 2011, 8 months.

Results were first posted in Dec 2017, 6 years 10 months after primary completion. A results delay was requested in Apr 2013.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2010
First posted
Mar 31, 2010
StartActual
May 17, 2010
Primary completionActual
Feb 9, 2011
CompletionActual
Feb 25, 2011
Results delay requested
Apr 10, 2013
Results first posted
Dec 13, 2017
Last update
Sep 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01096667
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 31, 2010
Start date
May 17, 2010
Primary completion
Feb 9, 2011
Completion
Feb 25, 2011
Results posted
Dec 13, 2017
Last update
Sep 13, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion